These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

156 related items for PubMed ID: 11474633

  • 1. Efficacy and safety of gemifloxacin in the treatment of community-acquired pneumonia: a randomized, double-blind comparison with trovafloxacin.
    File TM, Schlemmer B, Garau J, Cupo M, Young C, 049 Clinical Study Group.
    J Antimicrob Chemother; 2001 Jul; 48(1):67-74. PubMed ID: 11474633
    [Abstract] [Full Text] [Related]

  • 2. Efficacy and safety of gemifloxacin in the treatment of community-acquired pneumonia: a randomized, double-blind comparison with trovafloxacin.
    Hammerschlag MR.
    J Antimicrob Chemother; 2001 Nov; 48(5):735. PubMed ID: 11679567
    [No Abstract] [Full Text] [Related]

  • 3. Efficacy of gemifloxacin in acute exacerbations of chronic bronchitis: a randomised, double-blind comparison with trovafloxacin.
    Ball P, Wilson R, Mandell L, Brown J, Henkel T, 069 Clinical Study Group.
    J Chemother; 2001 Jun; 13(3):288-98. PubMed ID: 11450888
    [Abstract] [Full Text] [Related]

  • 4. Gemifloxacin once daily for 5 days versus 7 days for the treatment of community-acquired pneumonia: a randomized, multicentre, double-blind study.
    File TM, Mandell LA, Tillotson G, Kostov K, Georgiev O.
    J Antimicrob Chemother; 2007 Jul; 60(1):112-20. PubMed ID: 17537866
    [Abstract] [Full Text] [Related]

  • 5. Oral gemifloxacin versus sequential therapy with intravenous ceftriaxone/oral cefuroxime with or without a macrolide in the treatment of patients hospitalized with community-acquired pneumonia: a randomized, open-label, multicenter study of clinical efficacy and tolerability.
    Lode H, File TM, Mandell L, Ball P, Pypstra R, Thomas M, 185 Gemifloxacin Study Group.
    Clin Ther; 2002 Nov; 24(11):1915-36. PubMed ID: 12501883
    [Abstract] [Full Text] [Related]

  • 6. A prospective, double-blind, multicenter study comparing clarithromycin extended-release with trovafloxacin in patients with community-acquired pneumonia.
    Sokol WN, Sullivan JG, Acampora MD, Busman TA, Notario GF.
    Clin Ther; 2002 Apr; 24(4):605-15. PubMed ID: 12017405
    [Abstract] [Full Text] [Related]

  • 7. Efficacy and safety of gemifloxacin 320 mg once-daily for 7 days in the treatment of adult lower respiratory tract infections.
    Ball P, File TM, Twynholm M, Henkel T.
    Int J Antimicrob Agents; 2001 Jul; 18(1):19-27. PubMed ID: 11463522
    [Abstract] [Full Text] [Related]

  • 8. Gemifloxacin once daily for 7 days compared to amoxicillin/clavulanic acid thrice daily for 10 days for the treatment of community-acquired pneumonia of suspected pneumococcal origin.
    Léophonte P, File T, Feldman C.
    Respir Med; 2004 Aug; 98(8):708-20. PubMed ID: 15303634
    [Abstract] [Full Text] [Related]

  • 9. Trovafloxacin versus high-dose amoxicillin (1 g three times daily) in the treatment of community-acquired bacterial pneumonia.
    Trémolières F, de Kock F, Pluck N, Daniel R.
    Eur J Clin Microbiol Infect Dis; 1998 Jun; 17(6):447-53. PubMed ID: 9758291
    [Abstract] [Full Text] [Related]

  • 10. Efficacy and safety of ten day moxifloxacin 400 mg once daily in the treatment of patients with community-acquired pneumonia. Community Acquired Pneumonia Study Group.
    Patel T, Pearl J, Williams J, Haverstock D, Church D.
    Respir Med; 2000 Feb; 94(2):97-105. PubMed ID: 10714413
    [Abstract] [Full Text] [Related]

  • 11. Gemifloxacin for the treatment of respiratory tract infections: in vitro susceptibility, pharmacokinetics and pharmacodynamics, clinical efficacy, and safety.
    Bhavnani SM, Andes DR.
    Pharmacotherapy; 2005 May; 25(5):717-40. PubMed ID: 15899734
    [Abstract] [Full Text] [Related]

  • 12. Role of gemifloxacin in community-acquired pneumonia.
    Tillotson GS.
    Expert Rev Anti Infect Ther; 2008 Aug; 6(4):405-18. PubMed ID: 18662107
    [Abstract] [Full Text] [Related]

  • 13. Randomized, double-blind, comparative study of grepafloxacin and amoxycillin in the treatment of patients with community-acquired pneumonia.
    O'Doherty B, Dutchman DA, Pettit R, Maroli A.
    J Antimicrob Chemother; 1997 Dec; 40 Suppl A():73-81. PubMed ID: 9484876
    [Abstract] [Full Text] [Related]

  • 14. Gemifloxacin: a new fluoroquinolone approved for treatment of respiratory infections.
    Yoo BK, Triller DM, Yong CS, Lodise TP.
    Ann Pharmacother; 2004 Dec; 38(7-8):1226-35. PubMed ID: 15187209
    [Abstract] [Full Text] [Related]

  • 15. Treatment of acute exacerbations of chronic bronchitis: comparison of trovafloxacin and amoxicillin in a multicentre, double-blind, double-dummy study. Trovafloxacin Bronchitis Study Group.
    O'Doherty B, Daniel R.
    Eur J Clin Microbiol Infect Dis; 1998 Jun; 17(6):441-6. PubMed ID: 9758290
    [Abstract] [Full Text] [Related]

  • 16. Comparison of the efficacy and safety of moxifloxacin and trovafloxacin for the treatment of acute, bacterial maxillary sinusitis in adults.
    Klossek JM, Siegert R, Nikolaidis P, Arvis P, Leberre MA, Sinusitis Study Group.
    J Laryngol Otol; 2003 Jan; 117(1):43-51. PubMed ID: 12590855
    [Abstract] [Full Text] [Related]

  • 17. Gemifloxacin for community-acquired pneumonia.
    Lode HM, Schmidt-Ionas M, Stahlmann R.
    Expert Opin Investig Drugs; 2008 May; 17(5):779-86. PubMed ID: 18447602
    [Abstract] [Full Text] [Related]

  • 18. Gemifloxacin: a new, potent fluoroquinolone for the therapy of lower respiratory tract infections.
    File TM, Tillotson GS.
    Expert Rev Anti Infect Ther; 2004 Dec; 2(6):831-43. PubMed ID: 15566328
    [Abstract] [Full Text] [Related]

  • 19. Gemifloxacin versus amoxicillin/clavulanate in the treatment of acute exacerbations of chronic bronchitis. The 070 Clinical Study group.
    File T, Schlemmer B, Garau J, Lode H, Lynch S, Young C.
    J Chemother; 2000 Aug; 12(4):314-25. PubMed ID: 10949981
    [Abstract] [Full Text] [Related]

  • 20. A randomized, double-blind study comparing 5 days oral gemifloxacin with 7 days oral levofloxacin in patients with acute exacerbation of chronic bronchitis.
    Sethi S, Fogarty C, Fulambarker A.
    Respir Med; 2004 Aug; 98(8):697-707. PubMed ID: 15303633
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.